OUR PIPELINE IS POISED TO DELIVER NOW AND IN THE FUTURE

TARGET APPROVAL	FY20	FY21	FY22	FY23	FY24	FY25/26	FY27 AND BEYOND
ONCOLOGY		**mobocertinib** *2L NSCLC with EGFR exon 20 insertion mutation*[3]	**pevonedistat** *HR-MDS*	**mobocertinib** *1L NSCLC with EGFR exon 20 insertion mutation*	**pevonedistat** *Unfit AML* **TAK-007** *CD19+ hematologic malignancies*	**TAK-981** *Multiple cancers* **TAK-573** *R/R MM* **TAK-605** *Multiple cancers*	**TAK-252** *Solid tumors* **TAK-676** *Solid tumors* **TAK-102** *Multiple cancers* **TAK-940** *CD19+ hematologic malignancies* **TAK-186** *EGFR Solid Tumor*
RARE GENETIC & HEMATOLOGY		**maribavir** *R/R CMV infect. in transplant* **TAK-609** *Hunter CNS (IT)*	**maribavir** *1L CMV infect. in HSCT*	**TAK-611** *MLD (IT)* **TAK-755** *cTTP*		**TAK-755** *iTTP, SCD* **mezagitamab** *MG, ITP*	**TAK-607** *Complications of prematurity*
NEUROSCIENCE				**soticlestat** *DS* **soticlestat** *LGS*	**Orexin2R-ag** *(TAK-994/TAK-925) Narcolepsy T1*	**Orexin2R-ag** *Sleep Disorders*	**TAK-341** *Parkinson's Disease* **TAK-041** *Anhedonia in MDD* **TAK-071** *Parkinson's Disease* **TAK-653** *TRD* **TAK-831** *CIAS NS*
GASTRO-ENTEROLOGY		**Eohilia**[4] *EoE Approval date TBD*				**TAK-062** *Celiac Disease* **TAK-999** *AAT Liver Disease* **TAK-101** *Celiac Disease* **TAK-951** *Nausea & vomiting*	**sibofimloc** *Crohn's Disease (post-op and ileitis)* **TAK-906** *Gastroparesis* **TAK-954** *POGD* **TAK-671** *Acute Pancreatitis* **TAK-039** *Hepatic encephalopathy*
VACCINES		**TAK-003** *Dengue Vaccine* **TAK-919** *Moderna COVID-19 Vaccine (JP)* **TAK-019** *Novavax COVID-19 Vaccine (JP)*				**TAK-426** *Zika Vaccine*	**TAK-214** *Norovirus Vaccine*
PDT							

WAVE 1[1] | CLINICAL-STAGE NMEs | WAVE 2[2]

Orphan Potential in at Least One Indication · Breakthrough and/or Fast Track Designations · China Breakthrough and/or Japan SAKIGAKE Designation · New Addition to the Pipeline · COVID-19 Vaccines

1. Projected approval dates depend on data read-outs; some Wave 1 target approval dates assume accelerated approval
2. Certain Wave 2 programs may be accelerated into Wave 1 depending on future data read outs
3. Approval date assumes filing on Phase 2 data
4. In active discussions with the FDA. Projected approval subject to outcome of discussions

Takeda's Fiscal Year ends March 31 of the following year; e.g."FY20" refers to the twelve month period ending March 31, 2021.
All timelines are approximate estimates of April 6, 2021.

MAXIMIZING THE VALUE OF OUR APPROVED AND REGIONAL THERAPIES

	PHASE 1 & 2	PHASE 3	FILED
ONCOLOGY	**NINLARO**® Proteasome inhibitor R/R MM triplet Tx (US, EU) **ALUNBRIG**® ALK inhibitor 2L ALK+NSCLC 2nd gen TKI (GL) **NINLARO**® Proteasome inhibitor R/R MM doublet Tx (US, EU)	**ALUNBRIG**® ALK inhibitor 1L ALK+NSCLC (CN) **NINLARO**® Proteasome inhibitor Maint. ND MM no SCT (US, EU, CN) **NINLARO**® Proteasome inhibitor Maint. ND MM post-SCT (US, EU) **ALUNBRIG**® ALK inhibitor 2L ALK+NSCLC H2H with alectinib (GL) **ICLUSIG**® BCR-ABL inhibitor FL Ph+ ALL (US) **Cabozantinib** *Exelixis* VEGFR/RTK inhibitor 2L mNSCLC combo w/atezolizumab (JP) **Cabozantinib** *Exelixis* VEGFR/RTK inhibitor mCRPC combo w/atezolizumab (JP)	**NINLARO**® Proteasome inhibitor Maint. ND MM no SCT (JP) **Cabozantinib** *Exelixis* VEGFR/RTK inhibitor 2L HCC (JP) **ALUNBRIG**® ALK inhibitor 1L & 2L ALK+NSCLC (JP) **ICLUSIG**® BCR-ABL inhibitor TKI res. chronic phase CML (US) **ADCETRIS**® *Seattle Genetics* CD30 ADC CTCL (CN) **Cabozantinib** *Exelixis* VEGFR/RTK inhibitor 1L RCC combo w/nivolumab (JP)
RARE GENETIC & HEMATOLOGY	**NATPARA**® PTH replacement Hypothyrodism (JP)	**TAKHZYRO**® Anti-kallikrein mAb HAE pediatric (GL) **TAKHZYRO**® Anti-kallikrein mAb HAE (JP) **OBIZUR**® *Ipsen* FVIII replacement CHAWI (US, EU) **TAKHZYRO**® Anti-kallikrein mAb BMA (GL) **VONVENDI**® vWF replacement vWD Adult Prophylaxis (GL) **VONVENDI**® vWF replacement vWD Pediatric on-demand (GL) **ADYNOVATE**® Pediatric HemA (EU)	**TAKHZYRO**® Anti-kallikrein mAb HAE prophylaxis (CN)
NEUROSCIENCE			
GASTRO-ENTEROLOGY	**ENTYVIO**® α4β7 mAb Pediatric UC/CD (GL)	**ALOFISEL**® mesenchymal stem cells Perianal Fistulas in CD (US, JP) **ENTYVIO**® α4β7 mAb GvHD Prophylaxis (EU, JP) **ENTYVIO**® α4β7 mAb SubQ CD (US, JP) **Vonoprazan** PCAB Oral disintegrated tablet formulation (JP) **Vonoprazan** PCAB H. Pylori (CN)	**ENTYVIO**® α4β7 mAb SubQ UC (US, JP) **Vonoprazan** PCAB Reflex Esophagitis Maintenance (CN) **Vonoprazan** PCAB Duodenal ulcer (CN) **GATTEX**® GLP-2R agonist Pediatric-SBS (JP) **GATTEX**® GLP-2R agonist Adult-SBS (JP)
PDT	**CUVITRU**® IgG 20% (human) subcutaneous PID (JP) **HYQVIA**® *Halozyme* IgG 10% + Recombinant Human Hyaluronidase CIDP (US, EU) **HYQVIA**® *Halozyme* IgG 10% + Recombinant Human Hyaluronidase Pediatric PID (US)	

● Orphan Drug Designation (in any region / indication for a given asset) · Pivotal Ph-2 study · X Discontinued/deprioritized · ▶ Clinical stage up since Q2 FY20 · ✓ Approved since Q2 FY20

Pipeline as of April 6, 2021; region abbreviations: GL = global (USA, Europe, Japan, China). Pipeline not all inclusive; programs also ongoing in other Therapeutic Areas